PMID- 27075705
OWN - NLM
STAT- MEDLINE
DCOM- 20170426
LR  - 20170426
IS  - 1468-3083 (Electronic)
IS  - 0926-9959 (Linking)
VI  - 30
IP  - 7
DP  - 2016 Jul
TI  - A multicentre, randomized, single-blind comparison of topical clindamycin 
      1%/benzoyl peroxide 5% once-daily gel versus clindamycin 1% twice-daily gel in 
      the treatment of mild to moderate acne vulgaris in Chinese patients.
PG  - 1176-82
LID - 10.1111/jdv.13622 [doi]
AB  - BACKGROUND: Acne vulgaris affects up to 54% of Chinese adolescents. Combination 
      therapy has become the recommended standard of care for acne. OBJECTIVE: The aim 
      of this study was to compare the efficacy and safety of clindamycin (1%) and 
      benzoyl peroxide (5%) (CDP/BPO) gel once daily vs. clindamycin (1%) (CDP) 
      monotherapy gel twice daily in Chinese patients with mild to moderate acne. 
      METHODS: 1020 patients (aged 12-45 years) with mild to moderate acne were 
      randomized (1 : 1); 1016 patients were treated with CDP/BPO (n = 500) or CDP (n = 
      516) for a 12-week treatment period. Efficacy assessments were performed at 
      baseline, and at weeks 1, 2, 4, 8 and 12; and primarily included change in total 
      lesion count (inflammatory and non-inflammatory lesions), and proportion of 
      patients with a minimum 2-grade improvement in Investigator's Static Global 
      Assessment (ISGA) score. Patient safety and local tolerability were also 
      evaluated. RESULTS: Patients in CDP/BPO group showed a greater per cent reduction 
      in total lesion count compared with patients in CDP group at week 12 (delta = 
      -0.05; 95% CI = -0.09, -0.02; P = 0.003); statistically significant reduction in 
      lesion count was noted as early as week 1 and continued through week 12. A 
      greater proportion of patients in CDP/BPO group showed a >/=2-grade improvement in 
      ISGA score at week 12 compared with CDP group (30.2% vs. 22.7%; P = 0.018). 
      Overall, the incidence of adverse events (AEs) was higher in the CDP/BPO group 
      (14.4%) than in the CDP group (7.9%); the most commonly reported events were 
      generally related to application site reactions (erythema, pruritus and 
      swelling). Incidence of drug-related AEs was 8.6% in CDP/BPO group and 1.2% in 
      CDP group. Both groups showed trends towards reduction in investigator and 
      subject rated local tolerability scores. CONCLUSION: CDP/BPO gel demonstrated 
      superior efficacy over CDP gel along with acceptable safety and tolerability in 
      Chinese patients with mild to moderate acne. GOV NUMBER: NCT01915732.
CI  - (c) 2016 European Academy of Dermatology and Venereology.
FAU - Xu, J H
AU  - Xu JH
AD  - Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
FAU - Lu, Q J
AU  - Lu QJ
AD  - Hunan Key Laboratory of Medical Epigenomics, Department of Dermatology, Second 
      Xiangya Hospital, Central South University, Changsha, China.
FAU - Huang, J H
AU  - Huang JH
AD  - Department of Dermatology, Third Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Hao, F
AU  - Hao F
AD  - Department of Dermatology, Southwest Hospital, Third Military Medical University, 
      Chongqing, China.
FAU - Sun, Q N
AU  - Sun QN
AD  - Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences, Peking Union Medical College, Beijing, China.
FAU - Fang, H
AU  - Fang H
AD  - Department of Dermatology, The First Affiliated Hospital of Zhejiang University 
      School of Medicine, Hangzhou, China.
FAU - Gu, J
AU  - Gu J
AD  - Department of Dermatology, Changhai Hospital, Second Military Medical University, 
      Shanghai, China.
FAU - Dong, X Q
AU  - Dong XQ
AD  - Department of Dermatology, Guangdong General Hospital, Guangzhou, China.
FAU - Zheng, J
AU  - Zheng J
AD  - Department of Dermatology, Ruijin Hospital, Shanghai Jiaotong University School 
      of Medicine, Shanghai, China.
FAU - Luo, D
AU  - Luo D
AD  - Department of Dermatology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Li, F Q
AU  - Li FQ
AD  - Department of Dermatology, The Second Hospital of Jilin University, Changchun, 
      China.
FAU - Wang, G
AU  - Wang G
AD  - Department of Dermatology, Xijing Hospital, Fourth Military Medical University, 
      Xi'an, China.
FAU - Gu, H
AU  - Gu H
AD  - Institute of Dermatology, Chinese Academy of Medical Science and Peking Union 
      Medical College, Nanjing, China.
FAU - Tian, H Q
AU  - Tian HQ
AD  - Shandong Provincial Institute of Dermatology and Venereology, Provincial Academy 
      of Medical Science, Jinan, Shandong, China.
FAU - Yang, H L
AU  - Yang HL
AD  - Department of Dermatology, General Hospital of Guangzhou Military Command of PLA, 
      Guangzhou, China.
FAU - Xi, L Y
AU  - Xi LY
AD  - Department of Dermatology, Sun Yat-sen Memorial Hospital, Guangzhou, China.
FAU - Li, M
AU  - Li M
AD  - Department of Dermatology, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Zheng, M
AU  - Zheng M
AD  - Department of Dermatology, The Second Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, China.
FAU - Wu, Y
AU  - Wu Y
AD  - Department of Dermatology, Peking University First Hospital, Beijing, China.
FAU - Tu, Y T
AU  - Tu YT
AD  - Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - He, Y L
AU  - He YL
AD  - Department of Dermatology, Beijing Chao-Yang Hospital, Capital Medical 
      University, Beijing, China.
FAU - Zhao, G
AU  - Zhao G
AD  - Department of Dermatology, Air Force General Hospital, Beijing, China.
FAU - Sheng, W X
AU  - Sheng WX
AD  - Department of Dermatology, Zhongnan Hospital, Wuhan University, Wuhan, China.
FAU - Li, J
AU  - Li J
AD  - GlaxoSmithKline, Pudong, Shanghai, China.
FAU - Hamedani, A G
AU  - Hamedani AG
AD  - Stiefel, a GlaxoSmithKline Company, NC, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT01915732
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20160413
PL  - England
TA  - J Eur Acad Dermatol Venereol
JT  - Journal of the European Academy of Dermatology and Venereology : JEADV
JID - 9216037
RN  - 0 (Gels)
RN  - 3U02EL437C (Clindamycin)
RN  - W9WZN9A0GM (Benzoyl Peroxide)
SB  - IM
MH  - Acne Vulgaris/*drug therapy
MH  - Administration, Topical
MH  - Adolescent
MH  - Adult
MH  - Benzoyl Peroxide/*administration & dosage
MH  - Child
MH  - China
MH  - Clindamycin/*administration & dosage
MH  - Female
MH  - Gels
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Single-Blind Method
MH  - Young Adult
EDAT- 2016/04/15 06:00
MHDA- 2017/04/27 06:00
CRDT- 2016/04/15 06:00
PHST- 2015/09/30 00:00 [received]
PHST- 2016/01/06 00:00 [accepted]
PHST- 2016/04/15 06:00 [entrez]
PHST- 2016/04/15 06:00 [pubmed]
PHST- 2017/04/27 06:00 [medline]
AID - 10.1111/jdv.13622 [doi]
PST - ppublish
SO  - J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1176-82. doi: 10.1111/jdv.13622. 
      Epub 2016 Apr 13.